Allygen Biologics announced the completion of over RMB 300 million (≈ US$42 million) in Series A financing, led by Sherpa Healthcare Partners, with participation from the Beijing Medical and Health Industry Investment Fund, Qiming Venture Partners, Zhuhai Science and Technology Industry Group, Huagai Capital, TigerYeah Capital and W Capital. Proceeds will accelerate the company’s first STAR‑BiADC pipeline candidate, ALG01, into Phase 1 clinical trials, and support development of additional conjugate programs.
Financing Overview
| Item | Detail |
|---|---|
| Company | Allygen Biologics – innovative biotechnology, targeted conjugate drugs |
| Round | Series A, over RMB 300 million (≈ US$42 million) |
| Announcement Date | 13 Oct 2026 |
| Lead Investor | Sherpa Healthcare Partners |
| Co‑Investors | Beijing Medical and Health Industry Investment Fund; Qiming Venture Partners; Zhuhai Science and Technology Industry Group; Huagai Capital; TigerYeah Capital; W Capital |
| Use of Proceeds | Advance ALG01 (first STAR‑BiADC) into Phase 1; develop additional pipeline products |
Technology Platforms & Pipeline
- Core Technology – STAR: Proprietary Smart TME Activated Release technology, engineered to activate payload release within the tumor microenvironment (TME) for improved tumor‑selective killing and a wider therapeutic window.
- Platform 1 – Bi‑ADCs: Bispecific antibody‑drug conjugates, pairing dual‑antigen targeting with cytotoxic payload delivery.
- Platform 2 – AOCs: Antibody‑oligonucleotide conjugates, delivering oligonucleotide therapeutics to target cells.
- Platform 3 – ADOCs: Antibody‑drug‑oligonucleotide conjugates, a hybrid modality combining small‑molecule payloads and oligonucleotides on a single antibody backbone.
- Pipeline: Multiple candidates in development across various solid tumor indications; lead asset ALG01 – the company’s first STAR‑BiADC – is on track toward Phase 1 clinical trials.
- Modality Focus: Three integrated conjugate platforms covering the fast‑growing targeted conjugate landscape beyond conventional ADCs.
Pipeline Snapshot
| Attribute | Detail |
|---|---|
| Lead Asset | ALG01 (STAR‑BiADC) |
| Target / Indication | Solid tumors; specifics Not disclosed |
| Stage | Preclinical, advancing to Phase 1 with Series A proceeds |
| Platform Assets | Bi‑ADC, AOC and ADOC candidates – multiple programs in development |
Market Impact & Outlook
- Targeted Conjugate Momentum: The round reflects continued investor appetite for next‑generation conjugate modalities – bispecific ADCs, AOCs and ADOCs – as the field moves beyond first‑wave ADC successes.
- Blue‑Chip Syndicate: A consortium spanning Sherpa Healthcare Partners, Qiming Venture Partners, Huagai Capital and state‑backed funds (Beijing Medical and Health Industry Investment Fund, Zhuhai Science and Technology Industry Group) signals broad institutional conviction in Allygen’s platform strategy.
- Near‑Term Catalyst: The first value inflection point is ALG01’s Phase 1 entry, which will convert the STAR‑BiADC platform from preclinical promise into clinical validation.
- Strategic Flexibility: Three complementary platforms give Allygen optionality to pursue partnership and out‑licensing opportunities across distinct conjugate modalities as programs mature.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the use of financing proceeds, clinical development timelines and the potential of ALG01 and Allygen Biologics’ conjugate platforms. Actual results may differ materially due to risks including preclinical‑to‑clinical translation, regulatory requirements, trial outcomes and competitive dynamics.-Fineline Info & Tech
